Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norroa is a branded, RNA interference-based biopesticide used in beekeeping to control Varroa destructor mites in honey bee colonies. Developed by GreenLight Biosciences, it contains the active ingredient vadescana, a double-stranded RNA (dsRNA) oligonucleotide that targets an essential mite gene, interfering with production of a specific protein (including calmodulin) required for mite reproduction.[1][3][7][9] Delivered in sucrose-based pouches placed inside the hive, Norroa is ingested by bees and passed to larvae; phoretic and reproductive mites feeding on treated brood take up the dsRNA, which triggers RNAi-mediated degradation of the mite’s mRNA, preventing successful egg-laying and offspring production rather than directly killing adult mites.[1][3][7][9] Field trials across multiple U.S. regions have shown up to approximately 18 weeks of varroa control from a single application, with no observed adverse effects on adult bees, larvae, or queens, and with EPA registration as an environmentally targeted miticide classified in IRAC Group 35.[1][3][5][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Norroa.